Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +48.11%
#2 Pons Pons +36.58%
#3 Purr Purr +30.54%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +29.71%
#5 StonkBroker StonkBroker +27.42%
#6 TENDIES TENDIES +27.29%
#7 Starpower Starpower +27.21%
#8 Magma Finance Magma Finance +26.82%
#9 SkyAI SkyAI +24.81%
#10 PondCoin PondCoin +22.22%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Yumanity Therapeutics, Inc. Yumanity Therapeutics, Inc.

Yumanity Therapeutics, Inc.

YMTX
Classement en actions #28846
Yumanity Therapeutics Inc. operates as a clinical-stage biopharmaceutical... Yumanity Therapeutics Inc. operates as a clinical-stage biopharmaceutical company. Its primary focus lies in the investigation and development of therapeutic solutions for neurodegenerative conditions, particularly those driven by protein misfolding. The firm aims to discover disease-modifying treatments for a range of neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis (ALS), and frontotemporal lobar degeneration. Central to its pipeline is YTX-7739, an innovative small molecule presently in Phase I clinical trials for Parkinson's disease and associated α-synuclein disorders. Additionally, YTX-9184 is undergoing preclinical studies with the goal of treating diverse neurological conditions. The company maintains a license and research collaboration agreement with Merck Sharp & Dohme Corp. Founded in 2014, Yumanity Therapeutics Inc. is headquartered in Boston, Massachusetts.
Prix de l'action
$1.89
Dernière synchronisation: 2022-12-16
Capitalisation boursière
$24.38M
Changement (1 jour)
8.62%
Changement (1 an)
0.00%
Pays
US
Échange Yumanity Therapeutics, Inc. (YMTX)

Catégorie

Healthcare
Ratio P/B pour Yumanity Therapeutics, Inc. (YMTX)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Yumanity Therapeutics, Inc., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Yumanity Therapeutics, Inc. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 3.7087 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 2.5054 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH